Drug Shortage Report for REVATIO
| Report ID | 2036 |
| Drug Identification Number | 02279401 |
| Brand name | REVATIO |
| Common or Proper name | REVATIO |
| Company Name | UPJOHN CANADA ULC |
| Market Status | MARKETED |
| Active Ingredient(s) | SILDENAFIL |
| Strength(s) | 20MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 6x15 |
| ATC code | C02 |
| ATC description | OTHER ANTIHYPERTENSIVES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2017-01-19 |
| Estimated end date | 2017-03-15 |
| Actual end date | 2017-03-17 |
| Shortage status | Resolved |
| Updated date | 2017-03-18 |
| Company comments | Resolved March 17, 2017 / Résolu 17 mars 2017 |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 17300 TRANS CANADA HIGHWAY KIRKLAND, QUEBEC CANADA H9J 2M5 |
| Company contact information | Customer Service / service à la clientèle : 1-833-287-5646 Email / courriel: UpjohnCanadaCustomerService@pfizer.com |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2017-03-13 | English | Compare |
| v2 | 2017-03-13 | French | Compare |
| v3 | 2017-03-17 | English | Compare |
| v4 | 2017-03-17 | French | Compare |
| v5 | 2017-03-18 | English | Compare |
Showing 1 to 5 of 5